Presence of alternative lengthening of telomeres associated circular extrachromosome telomere repeats in primary leukemia cells of chronic myeloid leukemia
© Samassekou et al.; licensee BioMed Central Ltd. 2013
Received: 18 February 2013
Accepted: 23 March 2013
Published: 2 April 2013
The predominant mechanism by which human tumors maintain telomere length is via telomerase. In ~10% of tumor samples, however, telomere length is conserved, despite no detectable telomerase activity, in part through activation of the alternative lengthening of telomeres (ALT) pathway.
We studied the circular extra-chromosomal telomeric repeat (ECTR), an ALT hallmark, and telomerase activity in 24 chronic myeloid leukemia (CML) patients in chronic phase (CP).
We identified the presence of ECTR in primary leukemia cells from some of these samples, which indicates the possible involvement of an ALT mechanism. Moreover, we found that some samples exhibited both circular ECTR and telomerase activities, suggesting that both mechanisms can contribute to the onset of CML.
We propose that ALT or the combined activities of ALT and telomerase might be required for the early stages of leukemogenesis. These findings shed new light into the oncogenic pathways responsible for the maintenance of telomere length in leukemia, which will ultimately determine the effectiveness of anti-telomerase-based treatment protocols.
Human telomeres are long tandem arrays of TTAGGG bases associated with specialized nucleoprotein complexes localized at the physical ends of linear eukaryotic chromosomes that maintain the stability and the integrity of chromosomes . Normal somatic cells undergo a finite number of cell divisions. Each successive round of replication progressively shortens telomeres and once they reach a critical length they trigger a permanently differentiated cellular state termed replicative senescence. When cells become “transformed”, either by mutations or by viral oncogenes, the mechanisms limiting cell replication become inactivated and, as a consequence, telomeres shorten beyond a stable threshold, pushing these cells into crisis and death. Those cells that do survive and continue to replicate now have activated telomerase, an RNA-dependent DNA polymerase, or an alternative lengthening of telomeres (ALT) mechanism to specifically maintain telomere length and stabilize chromosome ends. ALT occurs in about 10% of human tumors  and uses homologous recombination (HR) mediated replication to specifically elongate telomeres, which often results in different sizes of telomeres . The use of HR by ALT positive cells can result in several cellular abnormalities which are considered “hallmarks” of activation of the pathway, including: 1) ALT-associated promyelocytic leukemia bodies (APBs), which are present in 5-35% of ALT cells , 2) telomere length heterogeneity ranging from 2 kb to greater than 20 kb in length [4, 5], and 3) the appearance of circular ECTR [6, 7], the latter of which is considered to be most reliable of all of the markers . While recombination-mediated ALT is thought of as the predominant mechanism that cells generate circular ECTRs, they can also arise from exposure to DNA damaging agents , overexpression of the telomerase catalytic subunit via telomere length trimming mechanism , or through catastrophic double-strand breaks that arise from overexpression of a truncated mutant of TRF2 lacking its basic domain .
Chronic myeloid leukemia (CML) is a malignant and clonal hematopoietic stem cell disorder characterized by overproduction of myeloid cells and a specific cytogenetic marker, the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11.2) . Without effective therapy, CML irremediably progresses through three phases: chronic (CP), accelerated (AP), and blast crisis (BP) phases. Like most cancer cells, the average length of telomeres of CML cells are shorter than that of normal cells and this telomere shortening is more pronounced during disease progression , despite the fact that in the later stages of CML telomerase is highly expressed . In our recent study on individual telomere length in CML, we found that although global telomere lengths in CML patient samples were shorter than normal, they do harbor distinctly long chromosome-specific telomeres , suggesting a unique signature of telomere length heterogeneity.
We hypothesized that this heterogeneity is probably the result of an active ALT pathway and not solely due to enhanced telomerase activity. In the present study, we show direct evidence for the presence of circular ECTR in CML, specifically the C-circles, indicating that ALT-mediated telomere regulation occurs in CML at a much higher frequency than previously thought.
Results and discussion
Summary of telomerase and 2D gel results in CML samples
ALT-dependent cells usually show little to no telomerase activity and have abundant ECTR in both linear and circular forms, especially C-stranded circles , caused by a t-loop deletion [10, 15]. The presence of telomere C-circles in 3 out the 11 ECTR positive samples with no/low telomerase activity strongly indicates the use of ALT mechanism to maintain telomeres in these samples. Moreover, the five samples which displayed telomeric double-strand and G-strand circles with no/low telomerase activity might also suggest the ALT mechanism in these samples. Alternatively, the presence of telomere double-strand circles can also be due to dysfunctional TRF2, which can induce homologous recombination and lead to the resolution of the t-loop . Furthermore, the presence of double-strand telomere circles with high telomerase activity might either be due to telomere uncapping defect in telomerase positive cells or the co-occurrence of both telomerase and ALT mechanisms in maintaining telomeres. The presence of both telomerase and ALT in telomere elongation appears to be a very rare phenomenon, but has been reported in only a few tumor types in general less than <5% of most tumor samples [16, 17]. Nevertheless, in mouse models, the presence of an active telomerase did not prevent telomere recombination from occurring . Therefore, it is feasible that these two mechanisms can act jointly or alternately to maintain telomere length in the same leukemia sample.
Even though telomere lengths of typical ALT cell lines are heterogeneous, generating some very long telomeres (more than 20 kb) in some cases , most of our CML samples (including those with circular ECTR) were associated with short telomeres (an average of 6.64 kb) . Although somewhat unusual, this phenomenon of homogeneously short telomeres in an ALT cell line has been previously documented . Similarly, cells derived from the telomerase deficient mTR-/- mouse model have been shown to maintain their telomere lengths by a recombination-based mechanism without extensive telomere elongation as seen in many ALT cell lines . Perhaps, these cells might use the same break-induced recombination mechanism to maintain their telomere lengths as seen in yeast type I telomerase-deficient survivor clones . Furthermore, the recombination mechanism in this mouse model led to at least a five-fold difference in the lengths of telomeres on p- and q- arms of a given chromosome  which is what we have seen previously in these CML samples [14, 23]. Thus, it seems likely that CML cells during CP might rely on a similar recombination mechanism as described in these different models in order to maintain their telomeres.
We proposed the following step-wise model to explain the transition from ALT to telomerase in the maintenance of telomeres during CML disease progression. In the early stages of CML leukemogenesis, ALT may act on a few specific chromosomes at first, perhaps by elongating telomeres on some key pro-growth or pro-survival chromosomes, conferring a cell proliferative advantage and thus leading to the formation of a leukemia cell clone . With the progression of the disease, eventual activation of telomerase would take over telomere length maintenance for most chromosomes in the cell, which would explain the presence of high telomerase activity in all of the CML samples studied during BP . This might also explain why some cells score positive for both telomere elongation mechanisms (Figure 3A): these are cells that are transitioning between both such that they have overlapping ALT and telomerase expression.
In summary, this study is the first (to our knowledge) to demonstrate in CML during CP a high frequency of circular ECTR (specifically C-circles), one of the defining hallmarks of ALT pathway activation. The presence of ALT in CML during the CP strongly suggests that ALT might be required at the early stages of leukemogenesis, potentially by conferring a necessary proliferative advantage. The fact that later stage CML cells always display activated telomerase  suggests a model in which CML disease state progresses from ALT to telomerase in order to preserve telomere length and might reflect a transition between chronic and blast crisis phases. It will be important to determine how other cancers of given disease state or mutational status governs telomere length maintenance mechanisms. Clearly, these results will have a significant impact in the development of anti-telomerase based chemotherapies in cancer, since the presence of ALT will be an important determinant for drug resistance ultimately hindering patient treatment outcome.
Primary leukemia cells from blood or bone marrow of 24 CML patients in chronic phase (CP) were obtained from the Quebec Leukemia Cell Bank (Research Centre, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada). The diagnoses for all patients were confirmed by the presence of the Philadelphia (Ph) chromosome as the sole abnormality using conventional cytogenetics and fluorescence in situ hybridization (FISH) techniques before any specific treatment in the Quebec Leukemia Cell Bank.
Telomerase activity was measured for each sample using the Quantitative Telomerase Detection Kit (Allied Biotech Inc., Germantown, MD, USA) according to the manufacturer's protocol, which is based on a PCR-based telomeric repeat amplification protocol. Briefly, 1×106 cells were washed once in 1x PBS and then centrifuged at 12,000 g for 2 min at 4°C. The cell pellet was resuspended in 200 μL of lysis buffer (provided by the kit). Following incubation on ice for 30 minutes, the cell pellet was re-centrifuged at 12,000 g for 30 min at 4°C. Supernatant containing 100 ng of total protein from each sample extract was used to detect for telomerase activity. As a negative control, an equal amount of sample (100 ng) was heat inactivated at 80°C for 15 min. The positive control (provided by the kit) was used to generate a standard curve using six 5-fold serial dilutions which ranged in concentration from 0.5 pM to 0.00016 pM. Each serial dilution was amplified in a 25 μL PCR reaction containing 12.5 μL 2x QTD Premix (provided by the kit), 1 μL of the diluted control template and 11.5 μL H2O. For each sample (including both positive and negative control) a similar 25 μL reaction mix was prepared, using 12.5 μl 2x QTD Premix and 100 ng of total protein from each sample adjusted to a total volume of 25 μL with H2O. The PCR amplification was done on a Rotor-Gene 3000 qPCR machine (Corbett Life Science) using a 2-step reaction with the following parameters: an initial telomerase reaction at 25°C for 20 min followed by a PCR reaction cycle consisting of an activation step at 95°C for 10 min and 35 cycles of 1) a denaturation step at 95°C for 30 s, 2) an annealing step at 60°C step for 30 s, and 3) an extension step 72°C for 30 s. We plotted a standard curve using the Ct values and the concentration of the serial dilutions of the control template, from which we interpolated the activity of telomerase activity for each CML relative to the normal controls. All samples and controls were tested in triplicate. Telomerase activity of each CML sample was expressed as fold-increase to the average telomerase activity of three normal samples. An arbitrary cut off to differentiate low telomerase activity from high telomerase activity was defined as the lower bound of the 95% confidence interval of the average fold-increase calculated from all CML samples.
In order to assess the involvement of ALT in these CML samples we scored for the presence of circular ECTR by resolving telomeric-C and/or G-strands using 2D gel electrophoresis following a protocol previously reported by others  with minor modifications. Briefly, genomic DNA was extracted from cryopreserved blood or bone marrow of all CML samples and digested with HinfI and RsaI (New England Biolabs, Ont, Canada). The digested DNA was electrophoresed in the first dimension on a 0.4% agarose gel at 1 V/cm and at 4°C for a period of about 20 hours. Then, gel slabs from appropriate lanes were excised and run in a 1% agarose gel in the second dimension at 5 V/cm and at 4°C for a period of about 10 hours, which depended upon the gel apparatus used and the size of the specific telomere under study. The DNA was subsequently blotted onto nylon membrane in 20X SSC. The hybridization and detection of the telomeric DNA were accomplished by following our previous terminal restriction fragment (TRF) protocol  using digoxigenine labeled (CCCTAA)3 and (TTAGGG)3 probes (IDT, San Jose, CA) to detect the telomeric G- and C-strands, respectively. The local research ethic committees of all involved institutions approved the protocols used in this study and informed consent was obtained from each donor.
In chronic myeloid leukemic at the chronic phase, an important proportion of cells presented extra chromosomal telomeric circles (specifically C-circles), hallmark of alternative lengthening of telomere, when telomerase is either present or not.
The authors would like to thank Mr. Yifei Yan for the important assistance in data analysis of the manuscript. We also thank Dr. Régen Drouin and Nathalie Bastien for the important comments and suggestions for this work. Clinical specimens were collected and analyzed by the Banque de cellules leucémiques du Québec (BCLQ) of the Réseau de recherche sur le cancer of the Fonds de Recherche du Québec - Santé, which is affiliated with the Canadian Tumour Repository Network. This study was supported by the Cancer Research Society Inc to JY; OS held a doctoral studentship from the “Fondation des Étoiles”; and JH is supported by a grant from the Cancer Research Network of Fonds de Recherche du Québec - Santé.
- Zakian VA: Telomeres: beginning to understand the end. Science. 1995, 270: 1601-1607. 10.1126/science.270.5242.1601.View ArticlePubMedGoogle Scholar
- Henson JD, Cao Y, Huschtscha LI, Chang AC, Au AY, Pickett HA, Reddel RR: DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol. 2009, 27: 1181-1185. 10.1038/nbt.1587.View ArticlePubMedGoogle Scholar
- Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR: Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med. 1997, 3: 1271-1274. 10.1038/nm1197-1271.View ArticlePubMedGoogle Scholar
- Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR: Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 1999, 59: 4175-4179.PubMedGoogle Scholar
- Cesare AJ, Reddel RR: Telomere uncapping and alternative lengthening of telomeres. Mech Ageing Dev. 2008, 129: 99-108. 10.1016/j.mad.2007.11.006.View ArticlePubMedGoogle Scholar
- Nabetani A, Ishikawa F: Alternative lengthening of telomeres pathway: recombination-mediated telomere maintenance mechanism in human cells. J Biochem. 2011, 149: 5-14. 10.1093/jb/mvq119.View ArticlePubMedGoogle Scholar
- Cesare AJ, Griffith JD: Telomeric DNA in ALT cells is characterized by free telomeric circles and heterogeneous t-loops. Mol Cell Biol. 2004, 24: 9948-9957. 10.1128/MCB.24.22.9948-9957.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Fasching CL, Neumann AA, Muntoni A, Yeager TR, Reddel RR: DNA damage induces alternative lengthening of telomeres (ALT) associated promyelocytic leukemia bodies that preferentially associate with linear telomeric DNA. Cancer Res. 2007, 67: 7072-7077. 10.1158/0008-5472.CAN-07-1556.View ArticlePubMedGoogle Scholar
- Pickett HA, Cesare AJ, Johnston RL, Neumann AA, Reddel RR: Control of telomere length by a trimming mechanism that involves generation of t-circles. EMBO J. 2009, 28: 799-809. 10.1038/emboj.2009.42.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang RC, Smogorzewska A, de Lange T: Homologous recombination generates T-loop-sized deletions at human telomeres. Cell. 2004, 119: 355-10.1016/j.cell.2004.10.011.View ArticlePubMedGoogle Scholar
- de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982, 300: 765-767. 10.1038/300765a0.View ArticlePubMedGoogle Scholar
- Drummond M, Lennard A, Brummendorf T, Holyoake T: Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia. Leuk Lymphoma. 2004, 45: 1775-1781. 10.1080/10428190410001693542.View ArticlePubMedGoogle Scholar
- Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K: Telomeres and telomerase in hematologic neoplasia. Oncogene. 2002, 21: 680-687. 10.1038/sj.onc.1205075.View ArticlePubMedGoogle Scholar
- Samassekou O, Ntwari A, Hebert J, Yan J: Individual telomere lengths in chronic myeloid leukemia. Neoplasia. 2009, 11: 1146-1154.PubMed CentralView ArticlePubMedGoogle Scholar
- Tokutake Y, Matsumoto T, Watanabe T, Maeda S, Tahara H, Sakamoto S, Niida H, Sugimoto M, Ide T, Furuichi Y: Extra-chromosomal telomere repeat DNA in telomerase-negative immortalized cell lines. Biochem Biophys Res Commun. 1998, 247: 765-772. 10.1006/bbrc.1998.8876.View ArticlePubMedGoogle Scholar
- Costa A, Daidone MG, Daprai L, Villa R, Cantu S, Pilotti S, Mariani L, Gronchi A, Henson JD, Reddel RR, Zaffaroni N: Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res. 2006, 66: 8918-8924. 10.1158/0008-5472.CAN-06-0273.View ArticlePubMedGoogle Scholar
- Villa R, Daidone MG, Motta R, Venturini L, De Marco C, Vannelli A, Kusamura S, Baratti D, Deraco M, Costa A: Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res. 2008, 14: 4134-4140. 10.1158/1078-0432.CCR-08-0099.View ArticlePubMedGoogle Scholar
- Morrish TA, Greider CW: Short telomeres initiate telomere recombination in primary and tumor cells. PLoS Genet. 2009, 5: e1000357-10.1371/journal.pgen.1000357.PubMed CentralView ArticlePubMedGoogle Scholar
- Lau LM, Dagg RA, Henson JD, Au AY, Royds JA, Reddel RR: Detection of alternative lengthening of telomeres by telomere quantitative PCR. Nucleic Acids Res. 2013, 41: e34-10.1093/nar/gks781.PubMed CentralView ArticlePubMedGoogle Scholar
- Neumann AA, Watson CM, Noble JR, Pickett HA, Tam PP, Reddel RR: Alternative lengthening of telomeres in normal mammalian somatic cells. Genes Dev. 2013, 27: 18-23. 10.1101/gad.205062.112.PubMed CentralView ArticlePubMedGoogle Scholar
- Cerone MA, Autexier C, Londono-Vallejo JA, Bacchetti S: A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT. Oncogene. 2005, 24: 7893-7901. 10.1038/sj.onc.1208934.View ArticlePubMedGoogle Scholar
- Chen Q, Ijpma A, Greider CW: Two survivor pathways that allow growth in the absence of telomerase are generated by distinct telomere recombination events. Mol Cell Biol. 2001, 21: 1819-1827. 10.1128/MCB.21.5.1819-1827.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Samassekou O, Li H, Hébert J, Ntwari A, Wang H, Cliche CG, Bouchard E, Huang S, Yan J: Chromosome-arm-specific long telomeres: a new clonal event in primary chronic myelogenous leukemia cells. Neoplasia. 2011, 13: 550-560.PubMed CentralView ArticlePubMedGoogle Scholar
- Ohyashiki K, Ohyashiki JH, Iwama H, Hayashi S, Shay JW, Toyama K: Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia. 1997, 11: 190-194. 10.1038/sj.leu.2400560.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.